Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-11.69%
-0.25%
+5.60%
+2.96%
+3.28%
RARE
Ultragenyx Pharmaceu
$28.97
Chart
$27.41 (+5.69%)
$36.19 (-19.95%)
$39.18 (-26.06%)
$57.62 (-49.72%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-11.69%
-0.25%
+5.60%
+2.96%
+3.28%
RARE
Ultragenyx Pharmaceu
Current Price
$28.97
Login to view Ultragenyx Pharmaceu (RARE) recommendation from the last 90 days from financial news and social media.
Chart
$27.41 (+5.69%)
$36.19 (-19.95%)
$39.18 (-26.06%)
$57.62 (-49.72%)
RARE Latest Analysis
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates. Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2025 it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tue Aug 5, 2025
Ultragenyx Pharmaceutical GAAP EPS of -$1.17 beats by $0.13 revenue of $166.5M beats by $5.13M.
Tue Aug 5, 2025
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst.
Tue Jul 29, 2025
Ultragenyx Represents Intriguing Buying Opportunity Despite Recent Setbacks. HC Wainwright assumed coverage on ) on Monday representing an attractive opportunity at current levels.Analyst “.Intriguing buying opportunity in one of biopharma’.s most diversified rare disease-focused companies”. the analyst said.HC Wainwright assumed coverage at a Buy rating with .The analyst says Ultragenyx shares have primarily come under pressure due to investor disappointment in the interim readou
Mon Jul 28, 2025
Beyond The Numbers: 7 Analysts Discuss Ultragenyx Pharmaceutical Stock. During the last three months 7 analysts shared their evaluations of Ultragenyx Pharmaceutical (NASDAQ:) revealing diverse outlooks from ish to bearish.The table below summarizes their recent ratings showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.2410010000021001000002000In the assessment of 12-month price targets analysts unveil insights for Ultragenyx Pharmaceutical pre
Mon Jul 28, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
RARE Stock trends
RARE Stock performance
RARE Stock analysis
RARE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings